




Full Year 2024 Financial Results



Total Revenues

\$14.7B

Ex Divestitures: ~\$14.25B*

Adjusted EBITDA*

\$4.7B

Ex Divestitures: ~\$4.4B*

Free Cash Flow*
Excluding Transaction Costs

\$2.6B

Ex Divestitures: ~\$2.3B*

Adjusted EPS*

\$2.65

Ex Divestitures: ~\$2.50*

Full Year Divestiture-Adjusted Operational Revenue Growth of 2%*



"2024 was a good year for Viatriis with full year operational revenue growth of 2%, excluding divestitures, in line with our guidance. As we head into 2025, we are focused on driving strong commercial execution, advancing our pipeline—including several important late-stage development milestones for selatogrel, cenerimod and sotagliflozin and six Phase 3 readouts—prioritizing capital return with a focus on share repurchases, executing our remediation plan for Indore and beginning an enterprise-wide initiative to review our global infrastructure and identify additional cost savings."

– Scott A. Smith
Chief Executive Officer

Delivered on Our Strategic Pillars in 2024



**DIVERSIFIED & GROWING
BASE BUSINESS**

Seventh consecutive quarter of divestiture-adjusted operational revenue growth

Delivered new product revenues of \$582M in 2024

Completed planned divestitures to simplify and streamline our organization



**FINANCIAL STRENGTH &
SIGNIFICANT CASH FLOW**

Generated free cash flow of \$2.6B in 2024⁽¹⁾

Returned \$825M in capital to shareholders through dividend and share repurchases

Retired ~\$3.7B of debt in 2024 and achieved long-term gross leverage target, ending the year at 2.9x



**EXPANDING INNOVATIVE
PORTFOLIO**

Idorsia collaboration added two Phase 3 assets, selatogrel and cenerimod, both with blockbuster potential

Entered into exclusive licensing agreement for sotagliflozin in all markets outside of the U.S. and Europe

Building Sustainable Access at Scale



Supplying high-quality medicines to **~1 billion patients** around the world annually⁽²⁾

*Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our [Fourth Quarter and Full Year 2024 Financial Results press release](#) on our website.

⁽¹⁾ 2024 Free Cash Flow was \$2.0B. Excluding the impact of transaction costs primarily related to the divestitures of \$649M, 2024 Free Cash Flow was \$2.6B.

⁽²⁾ See our 2023 Sustainability Report page 4 for more information.



[Viatriis.com](#)



[LinkedIn](#)



[@ViatriisInc](#)



[@ViatriisInc](#)



[YouTube](#)



[Listen Well Podcast](#)